Comparison of Treatment Regimens for Ultra High-Risk Multiple Myeloma Patients and the Importance of Gene Expression Profiling

While the treatment of multiple myeloma has seen several recent advances, challenges still remain when approaching patients with high-risk disease, and experts agree that incorporating genomic testing is an important step in treatment. In the UK, the Muk Nine b: OPTIMUM trial is a pivotal trial looking into the treatment of high-risk patients, providing insights into the importance of genomics.

In this exclusive podcast, UK experts Graham Jackson MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, and Martin Kaiser, MD, FRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, share some insights into myeloma treatment from a UK perspective, discussing the importance of genomics, key updates from the OPTIMUM, MASTER, and Myeloma XI trials, and the importance of chromosome 1q.

The post Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics appeared first on VJHemOnc.